Abstract
The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.
Keywords: BNT162b2 vaccine; COVID-19; SARS-CoV-2; T-cell immunity.
【저자키워드】 COVID-19, SARS-CoV-2, BNT162b2 vaccine, T-cell immunity, 【초록키워드】 Efficacy, BNT162b2 vaccine, vaccination, Immunity, SARS-COV-2 infection, severe acute respiratory syndrome coronavirus-2, severe acute respiratory syndrome Coronavirus, immunization, vaccine dose, BNT162b2, Severe acute respiratory syndrome, cellular immunity, mRNA, respiratory, T-cell immunity, Coronavirus-2, dose, humoral, regimen, acute respiratory syndrome, acute respiratory syndrome coronavirus, second dose, infected individual, first dose, naïve individuals, individual, acute respiratory syndrome coronavirus-2, mRNA-based vaccines, while, mRNA-based vaccine, vaccination schedule, Effect, effective, investigated, increase, demonstrated, individuals, accelerated, infected with SARS-CoV-2, of BNT162b2, SARS-CoV-2 spike-specific, 【제목키워드】 Immunity, mRNA vaccine, T cell, dose, individual, Effect,